Inhibrx Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	1.4	0.2	1.8	1.32
Revenue Growth (YoY)	-19.26%	-88.89%	36.88%	-
Cost of Revenue	146.95	203.74	191.64	101.6
Gross Profit	-145.55	-203.54	-189.84	-100.29
Selling, General & Admin	49.58	59.84	29.35	15.04
Operating Expenses	49.58	59.84	29.35	15.04
Operating Income	-195.13	-263.39	-219.19	-115.32
Interest Expense	-9.01	-13.49	-31.84	-
Interest & Investment Income	8.24	10.94	11.92	-
Earnings From Equity Investments	-	-	-1.63	-
Other Non Operating Income (Expenses)	-0.28	0.08	-0.58	0
EBT Excluding Unusual Items	-196.18	-265.86	-241.32	-115.32
Merger & Restructuring Charges	41.1	-68.06	-0.04	-
Other Unusual Items	-	2,021	-	-
Pretax Income	-155.08	1,688	-241.36	-115.32
Income Tax Expense	0	0	0	0
Net Income	-155.09	1,688	-241.36	-115.33
Net Income to Common	-155.09	1,688	-241.36	-115.33
Shares Outstanding (Basic)	15	15	12	43
Shares Outstanding (Diluted)	15	15	12	43
Shares Change (YoY)	6.72%	27.17%	-72.77%	-
EPS (Basic)	-10.02	114.01	-20.48	-2.67
EPS (Diluted)	-10.03	112.62	-20.48	-2.67
Free Cash Flow	-143.44	-197.01	-197.9	-91.5
Free Cash Flow Per Share	-9.27	-13.15	-16.80	-2.12
Operating Margin	-13937.86%	-131693.50%	-12176.94%	-8769.81%
Profit Margin	-11077.57%	843786.00%	-13408.94%	-8769.96%
Free Cash Flow Margin	-10245.64%	-98503.00%	-10994.56%	-6957.95%
EBITDA	-192.52	-261.1	-217.99	-114.1
D&A For EBITDA	2.61	2.29	1.19	1.23
EBIT	-195.13	-263.39	-219.19	-115.32
Revenue as Reported	1.4	0.2	1.8	1.32

Updated Nov 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q